Medical Device News Magazine

Accelus Launches Ultra-Low Profile FlareHawk7™ Expandable Cage Implant & Innovative Instruments

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Accelus, a privately held medical technology company focused on accelerating the adoption of minimally invasive surgery (MIS) as the standard of care in spine, today announced the launch of FlareHawk7, a multidirectionally expandable lumbar fusion device that is inserted at an ultra-low profile of 7mm to help minimize neural retraction before expanding in both the cranial-caudal and medial-lateral planes to provide sagittal and coronal correction, foraminal height restoration, and the stability to promote fusion.

The FlareHawk7 platform also features a suite of instruments designed to facilitate surgeons’ technique preferences. For endoscopic TLIF procedures, surgeons can leverage access with instruments to allow direct visualization of disc preparation and implant delivery. For MIS procedures, surgeons are provided access to the disc space through Kambin’s triangle while also preserving the patient’s normal anatomy. And in a “mini-open” procedure, the need for neural retraction can be minimized thanks to the smaller insertion footprint that is similar in profile to a No. 2 pencil.

“FlareHawk7 enables me to do fully endoscopic interbody fusion as outpatient surgery, with the best endplate prep and great clinical results,” said Jian Shen, M.D., PhD, a world-renowned leader in endoscopic spine surgery.

FlareHawk7 permits concurrent expansion in height and width to restore disc height without sacrificing stability. It enters the disc space with a compact 7mm x 7mm profile and then expands up to 11mm x 12mm—a 57% increase in width and 72% increase in height—with 0° and 6° lordosis options. This provides a larger surface contact area to distribute load with the goal of reducing subsidence in weak, osteoporotic bone. The implant’s open architecture design also allows significant graft delivery through the implant and into the surrounding disc space.

“FlareHawk7 is a game changer,” said Jason Huffman, M.D., a recognized leader in minimally invasive spinal fusion and Director of the Huffman Clinic in Napa, Calif. “It enables me to quickly and effectively perform a thorough discectomy and interbody fusion with a kick-ass, multiplanar-expandable, structured cage while utilizing a minimally invasive, percutaneous approach through Kambin’s triangle.”

Dr. Paul Houle, M.D., board-certified neurosurgeon with Cape Cod Healthcare Neurosurgery in Hyannis, Mass. agrees. “Historically, my surgical options were greatly limited when patients presented with scarring,” Dr. Houle said. “However, FlareHawk’s narrow insertion profile means I can treat these patients from a single position posteriorly – something not offered by other products currently on the market.”

The first-of-its-kind FlareHawk® family of implants utilizes a PEEK shell and internal shim, providing a small insertion profile to minimize neural retraction during insertion and then allowing expansion in height, width and lordosis, designed to reduce subsidence, restore foraminal height and re-establish sagittal balance. Peer-reviewed studies have suggested FlareHawk’s Adaptive Geometry to be a potential contributor to the implant’s positive fusion rates, as well as to the absence of observed subsidence1-4, a concern with monolithic cages that present a mismatch in the modulus of elasticity between the implant and the bone. To date, over 10,500 FlareHawk cages have been implanted in more than 9,000 patients.

“No other implant represents our philosophies of Adaptive Geometry and Access Without Compromise™ as well as FlareHawk7 with its ultra-low 7mm insertion profile expanding to 11mm, a full 2mm wider than the average 9mm TLIF implant. This allows for less neural retraction yet more footprint than current devices,” said Chris Walsh, CEO of Accelus. “We refuse to be dogmatic in our approach, as FlareHawk7 enables endoscopic, percutaneous, mini-open, and two-implant open PLIF procedures—all benefiting from Accelus’s Access without Compromise promise.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”